Reactions Weekly

, Volume 1153, Issue 1, pp 4–4 | Cite as

Three new cases of immune thrombocytopenic purpura (ITP) were diagnosed in patients who had received alemtuzumab in a phase II trial, CAMMS223

Clinical study
  • 9 Downloads

Keywords

Public Health Multiple Sclerosis Corticosteroid Platelet Count American Academy 

REFERENCE

  1. 1.
    Sullivan H, CAMMS223 Study Group.ITP following treatment of multiple sclerosis patients with alemtuzumab in CAMMS223: case reports and risk management plan implementation. Neurology 68 (Suppl. 1): 206, No. 12, 20 Mar 2007Google Scholar

Copyright information

© Adis International limited or Adis Data Information BV 2007

Personalised recommendations